Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 1
2013 1
2014 1
2019 1
2020 2
2021 13
2022 6
2023 9
2024 9
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Chon HJ, Braconi C, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Salani F, De Rosa A, Lavacchi D, Foti S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: rapposelli ig. Eur J Cancer. 2024 Sep;208:114199. doi: 10.1016/j.ejca.2024.114199. Epub 2024 Jun 30. Eur J Cancer. 2024. PMID: 39002348
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Rimini M, Masi G, Lonardi S, Nichetti F, Pressiani T, Lavacchi D, Jessica L, Giordano G, Scartozzi M, Tamburini E, Pastorino A, Rapposelli IG, Daniele B, Martinelli E, Garajova I, Aprile G, Schirripa M, Formica V, Salani F, Winchler C, Bergamo F, Balsano R, Gusmaroli E, Lorenzo A, Landriscina M, Pretta A, Toma I, Pirrone C, Diana A, Leone F, Brunetti O, Brandi G, Garattini SK, Satolli MA, Rossari F, Fornaro L, Niger M, Zanuso V, De Rosa A, Ratti F, Aldrighetti L, De Braud F, Foti S, Rizzato MD, Vivaldi C, Stefano C, Rimassa L, Antonuzzo L, Casadei-Gardini A. Rimini M, et al. Among authors: rapposelli ig. Target Oncol. 2024 May;19(3):359-370. doi: 10.1007/s11523-024-01060-1. Epub 2024 May 1. Target Oncol. 2024. PMID: 38691295
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma.
Pedretti S, Palermo F, Braghin M, Imperato G, Tomaiuolo P, Celikag M, Boccazzi M, Vallelonga V, Da Dalt L, Norata GD, Marisi G, Rapposelli IG, Casadei-Gardini A, Ghisletti S, Crestani M, De Fabiani E, Mitro N. Pedretti S, et al. Among authors: rapposelli ig. Signal Transduct Target Ther. 2025 Jun 27;10(1):200. doi: 10.1038/s41392-025-02282-z. Signal Transduct Target Ther. 2025. PMID: 40571693 Free PMC article.
Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Molinari C, Marisi G, Laliotis G, Spickard E, Rapposelli IG, Petracci E, George GV, Dutta P, Sharma S, Malhotra M, Prochowski Iamurri A, Feliciani G, Liu MC, Ulivi P, Canale M, Saragoni L, Gallo G, Frassineti GL, Muratore M, Romeo A, Jurdi A, Martinelli G, Passardi A. Molinari C, et al. Among authors: rapposelli ig. Sci Rep. 2024 Nov 28;14(1):29536. doi: 10.1038/s41598-024-80855-8. Sci Rep. 2024. PMID: 39604448 Free PMC article.
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Lo Prinzi F, et al. Among authors: rapposelli ig. Oncologist. 2025 Mar 10;30(3):oyae256. doi: 10.1093/oncolo/oyae256. Oncologist. 2025. PMID: 39427227 Free PMC article.
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Rimini M, Fornaro L, Lo Prinzi F, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Nichetti F, Jae Chon H, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Corallo S, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Djaballah SA, Zanuso V, Malapelle U, Pepe F, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: rapposelli ig. J Natl Cancer Inst. 2025 Oct 1;117(10):2029-2043. doi: 10.1093/jnci/djaf155. J Natl Cancer Inst. 2025. PMID: 40608977
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants.
Milella M, Orsi G, di Marco M, Salvatore L, Procaccio L, Noventa S, Bozzarelli S, Garajova I, Vasile E, Giordano G, Macchini M, Cavaliere A, Gaule M, Bergamo F, Chiaravalli M, Palloni A, Carloni R, Bittoni A, Niger M, Rapposelli IG, Rodriquenz MG, Scartozzi M, Mosconi S, Giommoni E, Bernardini I, Paratore C, Spallanzani A, Bencardino K, Forti L, Tamburini E, Lonardi S, Scarpa A, Cascinu S, Tortora G, Sperduti I, Reni M. Milella M, et al. Among authors: rapposelli ig. Cancer Med. 2025 Feb;14(3):e70364. doi: 10.1002/cam4.70364. Cancer Med. 2025. PMID: 39861955 Free PMC article.
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.
Rimini M, Fornaro L, Prinzi FL, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Satake T, Peeters F, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pirrone C, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Couto N, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Alvim CM, Roque R, Farinea G, Salani F, De Rosa A, Lavacchi D, Camera S, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Corallo S, Kang M, Bekaii-Saab T, Esposito L, Boccaccino A, Vitiello F, Himmelsbach V, Landriscina M, Djaballah SA, Tesini G, Masi G, Vogel A, Lonardi S, Rimassa L, Casadei-Gardini A. Rimini M, et al. Among authors: rapposelli ig. Int J Cancer. 2025 Sep 15;157(6):1246-1259. doi: 10.1002/ijc.35481. Epub 2025 May 19. Int J Cancer. 2025. PMID: 40387725
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.
Vitiello F, Vivaldi C, Rizzato MD, Saborowski A, Antonuzzo L, Rossari F, Salani F, Kim JW, Rapposelli IG, Tamburini E, Rimini M, Prinzi FL, Satake T, Peeters F, Pressiani T, Lucchetti J, Abidoye O, Gallio C, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Qaisar A, Pastorino A, Castet F, Yoo C, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Parisi A, Diana A, Couto N, Chan SL, Garajova I, Roque R, Ikeda M, Niger M, Tonini G, Himmelsbach V, Landriscina M, Masi G, Vogel A, Lonardi S, Fornaro L, Rimassa L, Casadei-Gardini A, Adeva J, Spinelli GP, Personeni N, Rodriguez MG, Leo S, Alvim CM, Farinea G, Genovesi V, De Rosa A, Lavacchi D, Camera S, Dekervel J, Balsano R, Kang M, Tesini G, Esposito L, Boccancino A, Ahcene Djaballah S, Bekaii-Saab T. Vitiello F, et al. Among authors: rapposelli ig. Oncology. 2025 Aug 14:1-26. doi: 10.1159/000546856. Online ahead of print. Oncology. 2025. PMID: 40815107
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study.
Niger M, Nichetti F, Fornaro L, Pircher C, Morano F, Palermo F, Rimassa L, Pressiani T, Berardi R, Gardini AC, Sperti E, Salvatore L, Melisi D, Bergamo F, Siena S, Mosconi S, Longarini R, Arcangeli G, Corallo S, Delliponti L, Tamberi S, Fea E, Brandi G, Rapposelli IG, Salati M, Baili P, Miceli R, Ljevar S, Cavallo I, Sottotetti E, Martinetti A, Busset MDD, Sposito C, Di Bartolomeo M, Pietrantonio F, de Braud F, Mazzaferro V. Niger M, et al. Among authors: rapposelli ig. BMC Cancer. 2024 Apr 8;24(1):436. doi: 10.1186/s12885-024-12225-6. BMC Cancer. 2024. PMID: 38589856 Free PMC article. Clinical Trial.
59 results